Authors: Turatti, F Mezzanzanica, D Nardini, E Luison, E Maffioli, L Bombardieri, E de Lalla, C Canevari, S Figini, M

Citation: F. Turatti et al., Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2, CANCER IMMU, 49(12), 2001, pp. 679-686

Authors: Perico, ME Chinol, M Nacca, A Luison, E Paganelli, G Canevari, S

Citation: Me. Perico et al., The humoral immune response to macrocyclic chelating agent DOTA depends onthe carrier molecule, J NUCL MED, 42(11), 2001, pp. 1697-1703

Authors: Perico, ME Mezzanzanica, D Luison, E Alberti, P Panza, L Russo, G Canevari, S

Citation: Me. Perico et al., Development of a new vaccine formulation that enhances the immunogenicity of tumor-associated antigen CaMBr1, CANCER IMMU, 49(6), 2000, pp. 296-304

Authors: Rodolfo, M Melani, C Zilocchi, C Cappetti, B Luison, E Arioli, I Parenza, M Canevari, S Colombo, MP

Citation: M. Rodolfo et al., IgG2a induced by interleukin (IL) 12-producing tumor cell vaccines but notIgG1 induced by IL-4 vaccine is associated with the eradication of experimental metastases, CANCER RES, 58(24), 1998, pp. 5812-5817